Diag-Nose.io
Bethlehem, Pennsylvania, United States · Artificial Intelligence, Biotechnology, Health Care
Diag-Nose.io is a biotechnology company founded in 2020, focusing on precision diagnostic and drug discovery solutions for chronic respiratory diseases. Their technology integrates advanced proteomics, computational biology, and AI to enhance treatment prescription and accelerate new therapy development. The flagship platform, RhinoMAP™, aims to predict respiratory disease activity and monitor tre
Key facts
- Headquarters
- Bethlehem, Pennsylvania, United States
- Employees
- 7
- Industries
- Artificial Intelligence, Biotechnology, Health Care
- Status
- Private
- Website
- diag-nose.io
- Company page
Recent activity at Diag-Nose.io
Diag-Nose.io funding history
| Date | Round | Amount |
|---|---|---|
| Jan 2025 | Seed | $2.0M |
Leadership
- Brian Occhipinti, Engineer
- David Yen, Founder
Verified email and direct lines for Diag-Nose.io’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Diag-Nose.io in the news
- Development and validation of the predictive aplastic score system (PASS): a simplified tool to diagnose acquired aplastic anemia in adults - Nature (Apr 27, 2026)
- Prismatic Launches New Executions Experience to Help Teams Diagnose Integration Issues Faster - StreetInsider (Oct 01, 2026)
- AI-Powered Fundus Cameras Diagnose Diabetic Retinopathy in Seconds - Cleveland Clinic (Mar 31, 2026)
- ControllerTest.io is a web application that can diagnose controller drift. - GIGAZINE (May 03, 2026)
- Accuracy of type 2 inflammatory biomarkers to diagnose asthma in adults and children: a meta-analysis of 30 studies with prospective validation in an adult primary care cohort - The Lancet (Sep 15, 2026)
- New MS Diagnostic Criteria Updates - National Multiple Sclerosis Society (Oct 02, 2024)
- Customizable AI tool developed at Stanford Medicine helps pathologists identify diseased cells - Stanford Medicine (Jun 19, 2024)
- New – Amazon DevOps Guru for RDS to Detect, Diagnose, and Resolve Amazon Aurora-Related Issues using ML - Amazon Web Services (AWS) (Dec 01, 2021)
Companies similar to Diag-Nose.io
- Avalon Globocare Corp. · Artificial Intelligence, Biotechnology, Health Care, Health Diagnostics, Therapeutics
- Gaomei Gene · Artificial Intelligence, Biotechnology, Health Care, Health Diagnostics, Therapeutics
- WM Therapeutic Ltd · Artificial Intelligence, Biotechnology, Health Care, Health Diagnostics, Therapeutics
- Kordata Dynamics · Artificial Intelligence, Biotechnology, Health Care, Health Diagnostics, Therapeutics
- Dehaze GmbH · Artificial Intelligence, Biotechnology, Health Care, Health Diagnostics
About Diag-Nose.io: questions and answers
What does Diag-Nose.io do?
Diag-Nose.io is a biotechnology company founded in 2020, focusing on precision diagnostic and drug discovery solutions for chronic respiratory diseases. Their technology integrates advanced proteomics, computational biology, and AI to enhance treatment prescription and accelerate new therapy development. The flagship platform, RhinoMAP™, aims to predict respiratory disease activity and monitor tre
Where is Diag-Nose.io headquartered?
Diag-Nose.io is headquartered in Bethlehem, Pennsylvania, United States.
How many employees does Diag-Nose.io have?
Diag-Nose.io has about 7 employees.
Has Diag-Nose.io raised funding?
Yes. Fundz has recorded 1 funding event for Diag-Nose.io. The most recent, Seed of $2.0M, was in Jan 2025.
Who leads Diag-Nose.io?
David Yen is a Founder at Diag-Nose.io.
What is the latest news on Diag-Nose.io?
On Jan 30, 2025, Diag-Nose.io Opens Houston Office following $2M Seed Round
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy